Hoth Therapeutics filed two provisional patent applications with the U.S. Patent and Trademark Office, expanding the company’s intellectual property portfolio along with establishing a new oncology-focused dermatology platform targeting treatment-induced skin toxicity from modern cancer therapies.¹

The patent applications were filed under the titles of covering the topical treatment of radiation-induced skin toxicity in oncology patients and addressing dermatologic toxicities associated with emerging targeted cancer therapies, including second and third menin inhibitors, respectfully.¹

Why did Hoth file the patent applications together?

Hoth elected to submit both patent applications together to secure priority intellectual property rights around the use of HT-001, a receptor antagonist with a well-established pharmacologic profile targeting neurogenic and inflammatory pathways implicated in therapy-induced skin injuries to treat dermatologic toxicities across multiple oncology treatment modalities, including radiation therapy and next-generation targeted agents.¹

With cancer treatments becoming more effective and patients remaining on therapies longer, managing treatment-limiting skin toxicities has become a critical and growing unmet need in oncology care.¹

Both dermatitis and dermatologic adverse effects induced from radiotherapy and targeted oncology therapies commonly result in pain, inflammation, severe pruritus, infection risk, reduced quality of life, and treatment interruption or discontinuation, holding the potential to negatively impact patient outcomes.

Despite the prevalence, current treatment options have maintained support, with just a handful of mechanism-driven therapies being designed to address the underlying biological drivers of these conditions.¹

Along with securing priority intellectual property rights, Hoth also filed both patents to protect the use of HT-001 as a treatment to target both neurogenic and inflammatory pathways in therapy-induced skin injuries. Hoth believes this approach represents a potentially first-in-class strategy within both the oncology supportive-care and oncodermatology markets respectively.¹

As of December 3, 2025, Hoth was continuing its Phase II CLEER-001 clinical trial targeting EGFR-inhibitor–associated rash, with recent progress reports including, a strong safety profile with no dose-limiting toxicities currently observed, consistent improvement trends in rash severity and pruritus, and increased clinical-site engagement and favorable investigator feedback.²

Epidermal growth factor receptor inhibitors (EGFRI) are used widely to treat non-small cell lung cancer (NSCLC), pancreatic, breast, colorectal, and head and neck cancers, and are associated with dermatologic side effects in up to 90% of patients, typically resulting in painful rashes, pruritus, dryness, nail changes, and alopecia.³

"These filings represent a meaningful expansion of our intellectual property estate into an increasingly important area of oncology care," said Robb Knie, Hoth Therapeutics’ CEO. "As cancer therapies advance, the ability to manage treatment-related toxicities is becoming essential. We believe this emerging platform highlights our strategy of identifying differentiated, mechanism-driven opportunities that can address significant unmet needs while creating long-term shareholder value."

Hoth Therapeutics believes the patents can support oncology-adjacent platform development, including potential applications spanning across radiation oncology, targeted cancer therapies, dermatology, and inflammatory skin disorders, while leveraging an established compound in novel therapeutic contexts, formulations, and routes of administration.¹

The company also expects the patent filings to help provide it the ability to pursue additional preclinical development formulation optimization, and future U.S. and international patent protection.¹

Sources

1. Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform Hoth Therapeutics January 2, 2026 https://www.prnewswire.com/news-releases/hoth-therapeutics-expands-oncology-pipeline-with-dual-patent-filings-establishing-novel-oncology-dermatology-ip-platform-302651580.html
2. Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program Hoth Therapeutics December 3, 2025 https://www.prnewswire.com/news-releases/hoth-therapeutics-issues-comprehensive-pipeline-update-highlighting-clinical-progress-orphan-designated-ht-kit-advancing-ht-001-phase-2-and-new-gdnf-metabolic-program-302632120.html
3. Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects Hoth Therapeutics June 24, 2025 https://www.prnewswire.com/news-releases/hoth-therapeutics-ht-001-interim-results-first-in-class-topical-therapy-preserves-cancer-treatment-while-resolving-dermatologic-side-effects-302489805.html